Baird initiates coverage on ABT with a $121 target, citing steady growth in medical devices and diagnostics through 2028.
Baird initiated coverage on Abbott Laboratories (ABT) with an Outperform rating and a $121 price target. The firm expects steady top-line and earnings growth driven by the company’s medical device segment, which is projected to outperform peers. Diagnostics, nutrition, and established pharmaceuticals further strengthen Abbott’s market position.
The outlook includes upside potential in FY 2027 and FY 2028, supported by new product launches and synergies from Exact Sciences integration. Meanwhile, Evercore ISI adjusted its ABT price target to $112 from $120 while maintaining an Outperform rating, reflecting healthy sector trends in procedure volumes and capital expenditures.
Abbott’s diversified healthcare portfolio spans discovery, development, manufacturing, and sales of medical products. The firm’s analysis highlights long-term growth opportunities despite near-term market fluctuations.